AGEN

Agenus's stock price has been impacted by several key events over the past six months. In Q4 2025, the company reported earnings per share of -$0.37, beating analysts' expectations, and revenue for the quarter was $34.2 million, also surpassing estimates. The company swung to a profit in Q3 FY 2025, reporting total revenue of US$30.2 million and EPS of US$2.00. Agenus announced the first patient enrollment in the global Phase 3 BATTMAN trial for BOT plus BAL in metastatic colorectal cancer in May 2026. In April 2026, Agenus announced that four abstracts highlighting botensilimab, alone or in combination with balstilimab, were accepted for presentation at the 2026 ASCO Annual Meeting, including the first Phase 2 data in advanced cutaneous melanoma. Phase II data demonstrating immune reprogramming and durable survival with botensilimab, balstilimab, and agenT-797 in PD-1 refractory gastroesophageal cancer were also reported in April 2026. Agenus entered into a strategic collaboration with Zydus Lifesciences, involving the sale of biologics manufacturing facilities for $75 million upfront, contingent payments, an equity investment by Zydus, and an exclusive license for BOT and BAL in India and Sri Lanka. The share price has been highly volatile over the past three months, with an average weekly change of 22%, and was up 113% over the past year as of May 7, 2026.